Baxdrostat Placebo

DRUG6 trials

Sponsors

Astrazeneca AB, AstraZeneca AB

Conditions

Chronic kidney disease (CKD) and hypertension.Prevention of Heart failurePrimary Aldosteronism defined by excess aldosterone secretionResistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated doseUncontrolled hypertension (uTHN) defined as blood pressure that remains higher than goal levels despite patients being treated with 2 anti-hypertensive agentsincluding a diuretic.including a diuretic. Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose

Phase 3

A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension

CompletedCTIS2023-505499-32-00

Astrazeneca ABincluding a diuretic., including a diuretic. Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, Uncontrolled hypertension (uTHN) defined as blood pressure that remains higher than goal levels despite patients being treated with 2 anti-hypertensive agents

Start: 2024-03-08End: 2025-10-07Target: 205Updated: 2025-08-25

A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension.

CompletedCTIS2023-507640-36-00

Astrazeneca ABincluding a diuretic., Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose

Start: 2024-04-29End: 2025-08-08Target: 79Updated: 2025-07-04

A Phase III, Randomised, Double-Blind, Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure

Active, not recruitingCTIS2023-506457-38-00

Astrazeneca ABChronic kidney disease (CKD) and hypertension.

Start: 2024-06-05Target: 675Updated: 2025-11-06

A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney Disease and High Blood Pressure.

RecruitingCTIS2023-506460-14-00

Astrazeneca ABChronic kidney disease (CKD) and hypertension.

Start: 2025-05-07Target: 1134Updated: 2025-11-05

A Phase III, Randomised, Double-Blind, Placebo-controlled, Event driven Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death in Participants with Increased Risk of Developing Heart Failure

RecruitingCTIS2024-514506-32-00

AstraZeneca ABPrevention of Heart failure

Start: 2025-05-06Target: 3868Updated: 2025-11-03

A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants with Primary Aldosteronism

RecruitingCTIS2025-520740-16-00

AstraZeneca ABPrimary Aldosteronism defined by excess aldosterone secretion

Start: 2025-09-19Target: 49Updated: 2025-11-14